Cediranib Maleate Clinical Trial for Malignant Pleural Mesothelioma Patients
Malignant pleural mesothelioma is often treated with a chemotherapy combination of pemetrexed and cisplatin. Cancer cells thrive by splitting and dividing, resulting in metastasis of the mesothelioma to other organs. The combination of these two chemotherapy drugs slows or stops the growth of cancer cells in the body by inhibiting the enzyme action that is required for the cells to reproduce and spread.
Mesothelioma is an aggressive cancer, however, and is shown to be chemo-resistant in many cases. Researchers at Southwest Oncology Group are now testing the effect of adding cediranib maleate to the pemetrexed/cisplatin combination in patients with malignant pleural mesothelioma that have not been previously treated by surgery, chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for the mesothelioma.
Pleural mesothelioma is a form of lung cancer that is almost always caused by asbestos exposure and is most commonly found in the outer lining of the lungs called the mesothelium. Although there is no cure for mesothelioma, it can be treated with varying degrees of success through the use of surgical procedures, chemotherapy and radiation.
Cediranib maleate, also called AZD2171 and Recentin, may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of antiangiogenesis agent and a type of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor.
The purpose of this randomized phase I/II trial is to study the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin, and to see how well it works in treating patients with malignant pleural mesothelioma.
Southwest Oncology Group is one of the largest cancer clinical trials cooperative groups in the United States and is funded largely by research grants from the National Cancer Institute. More than 6,000 cancer patients and healthy participants are enrolled each year in Group studies, and approximately 35,000 more are involved annually in ongoing clinical trials.
See ClinicalTrials.gov for enrollment information.